Xencor to Present at Upcoming Investor Conferences
A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
- A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
- Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
- Currently, 17 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
- Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.